Therapy combination carries risk for patients with brain metastases

Therapies that unleash the immune system to fight tumors have greatly extended the lives of people with many types of cancer. But there are reports that patients with melanoma and lung cancer whose disease has spread to the brain may experience serious inflammatory reactions after receiving immunotherapy drugs concurrently with radiation. In a study appearing April 9 in JAMA Network Open, researchers at the Duke Center for Brain and Spine Metastasis report a nearly two-fold increase in the risk of symptomatic brain inflammation, termed radiation necrosis, among patients with brain metastases receiving the immunotherapies within four weeks of a form of targeted radiation therapy called radiosurgery.

Research Offers New Insights into Why Brain Tumor Immunotherapies Fail

A newly defined parameter may help explain why certain immunotherapies for brain tumors fail and therefore offer new opportunities to curb tumor progression, according to research led by Peter Fecci, MD, PhD, director of the Duke Center for Brain and Spine Metastasis.

Q&A: PuMP Trial for Recurrent Glioblastoma

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer. Click to read the full Q&A.

How Breast Cancer Spreads to a Vital Compartment of the Brain 

Research led by Dorothy Sipkins, MD, PhD, has identified a previously unknown shortcut that some #breastcancer cells use to metastasize to the leptomeninges — the thin membranes that protect the brain — as well as clues that suggest how to block this path.